Rethinking on the management strategy of malignant phyllodes tumor of the breast: An analysis based on the SEER database

Malignant phyllodes tumor of the breast (MPTB) is a rare breast neoplasm that has a high recurrence rate and its optimal treatment strategies remain controversial. Our study used the most up-to-date database to determine prognostic factors that predict cancer-specific survival (CSS) and to evaluate the effects of different treatment strategies for MPTB. We performed a retrospective cohort study using the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Women who were diagnosed with MPTB from 2000 to 2019 were included. Kaplan–Meier method and Cox proportional hazards regressions were used to evaluate the prognostic power of variables on CSS. A total of 1902 women with MPTB were included in the study, with a median follow-up duration of 87.5 months. Age was found not to independently predict CSS in patients with tumors larger than 10 cm (P = .235). Mastectomy was performed on a total of 898 (47.2%) patients including 210 women (23.4%) undergoing radiotherapy after surgery. Mastectomy showed worse CSS when compared with breast-conserving surgery in patients with tumors smaller than 10 cm. Patients undergoing radiotherapy were not inferior to non-radiotherapy patients on CSS when patients were stratified by tumor size. Breast-conserving surgery showed survival benefits for patients with small tumors (T1 and T2). Patients with radiotherapy were not inferior to non-radiotherapy patients on CSS. Treatment of patients with MPTB should be carefully selected based on different tumor sizes.

[1]  N. Hong,et al.  Phyllodes Tumors: A Scoping Review of the Literature , 2021, Annals of Surgical Oncology.

[2]  A. Farahat,et al.  Phyllodes tumors of the breast: Adjuvant radiation therapy revisited , 2021, Breast.

[3]  Tae Hyun Kim,et al.  Malignant and borderline phyllodes tumors of the breast: a multicenter study of 362 patients (KROG 16-08) , 2018, Breast Cancer Research and Treatment.

[4]  M. Knowling,et al.  Phyllodes tumors of the breast: The British Columbia Cancer Agency experience. , 2018, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[5]  Amy M. Sitapati,et al.  Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  G. Tse,et al.  Mammary phyllodes tumour: a 15-year multicentre clinical review , 2017, Journal of Clinical Pathology.

[7]  B. Poirier,et al.  How Wide Should Margins Be for Phyllodes Tumors of the Breast? , 2017, The breast journal.

[8]  Kyubo Kim,et al.  Radiation therapy for malignant phyllodes tumor of the breast: An analysis of SEER data. , 2017, Breast.

[9]  C. Greenberg,et al.  Current Trends in the Management of Phyllodes Tumors of the Breast , 2016, Annals of Surgical Oncology.

[10]  I. Ellis,et al.  Phyllodes tumours of the breast: a consensus review , 2016, Histopathology.

[11]  J. Mituś,et al.  Malignant Phyllodes Tumor of the Breast: Treatment and Prognosis , 2014, The breast journal.

[12]  S. Kulkarni,et al.  Utilization of Radiotherapy for Malignant Phyllodes Tumors: Analysis of the National Cancer Data Base, 1998–2009 , 2014, Annals of Surgical Oncology.

[13]  A. Luini,et al.  Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. , 2013, Critical reviews in oncology/hematology.

[14]  I. Ellis,et al.  Myoepithelial and epithelial–myoepithelial, mesenchymal and fibroepithelial breast lesions: updates from the WHO Classification of Tumours of the Breast 2012 , 2013, Journal of Clinical Pathology.

[15]  A. Khanna,et al.  Phyllodes Tumor of Breast: A Review Article , 2013, ISRN surgery.

[16]  J. Lee,et al.  Clinicopathologic Risk Factors for the Local Recurrence of Phyllodes Tumors of the Breast , 2012, Annals of Surgical Oncology.

[17]  M. Bollet,et al.  Management of Phyllodes Breast Tumors , 2011, The breast journal.

[18]  W. Wells,et al.  A Prospective, Multi-Institutional Study of Adjuvant Radiotherapy After Resection of Malignant Phyllodes Tumors , 2009, Annals of Surgical Oncology.

[19]  T. Schultheiss,et al.  Malignant phyllodes tumor of the breast: local control rates with surgery alone. , 2007, International journal of radiation oncology, biology, physics.

[20]  J. Tward,et al.  Malignant phyllodes tumor of the female breast , 2006, Cancer.

[21]  C. Tzen,et al.  Surgical treatment of phyllodes tumors of the breast: Retrospective review of 172 cases , 2005, Journal of surgical oncology.

[22]  J. Růžičková,et al.  Retrospective analysis of 25 women with malignant cystosarcoma phyllodes—treatment results , 2004, Archives of Gynecology and Obstetrics.

[23]  E. Abraham,et al.  Malignant Phyllodes Tumor , 2001, The breast journal.

[24]  S. A. Harries,et al.  Phyllodes tumours , 2001, Postgraduate medical journal.

[25]  K. Hunt,et al.  Primary treatment of cystosarcoma phyllodes of the breast , 2000, Cancer.

[26]  A. Stelmach,et al.  The treatment and prognosis of patients with phyllodes tumor of the breast: An analysis of 170 cases , 1996, Cancer.

[27]  L. Barnes,et al.  Cystosarcoma phyllodes. A clinicopathologic analysis of 42 cases , 1978, Cancer.

[28]  PhD Cha Kyong Yom MD,et al.  Reappraisal of Conventional Risk Stratification for Local Recurrence Based on Clinical Outcomes in 285 Resected Phyllodes Tumors of the Breast , 2015, Annals of Surgical Oncology.